Axon Enterprise, Inc. (NASDAQ:AXON) Receives $542.15 Average PT from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $561.31.

AXON has been the subject of several recent research reports. Robert W. Baird increased their price target on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Craig Hallum downgraded shares of Axon Enterprise from a “buy” rating to a “hold” rating and set a $625.00 price objective for the company. in a research report on Thursday. TD Cowen initiated coverage on Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price objective on the stock. Finally, Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th.

Axon Enterprise Stock Down 5.3 %

AXON stock opened at $513.22 on Wednesday. Axon Enterprise has a twelve month low of $265.32 and a twelve month high of $715.99. The stock has a market cap of $39.13 billion, a P/E ratio of 132.62, a PEG ratio of 5.43 and a beta of 1.05. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average is $619.94 and its two-hundred day moving average is $519.86.

Insider Activity

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the transaction, the director now directly owns 6,929 shares in the company, valued at $4,185,601.03. This represents a 6.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jeffrey C. Kunins sold 2,304 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $654.79, for a total transaction of $1,508,636.16. Following the transaction, the insider now directly owns 128,542 shares of the company’s stock, valued at $84,168,016.18. This trade represents a 1.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,711 shares of company stock worth $5,631,561 over the last three months. 6.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC raised its holdings in Axon Enterprise by 7.9% in the third quarter. Bleakley Financial Group LLC now owns 1,507 shares of the biotechnology company’s stock valued at $602,000 after buying an additional 110 shares during the period. Stratos Wealth Advisors LLC purchased a new position in Axon Enterprise in the third quarter valued at about $259,000. Blue Trust Inc. lifted its stake in shares of Axon Enterprise by 234.5% during the third quarter. Blue Trust Inc. now owns 291 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 204 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Axon Enterprise by 7.5% in the third quarter. Commonwealth Equity Services LLC now owns 75,201 shares of the biotechnology company’s stock valued at $30,050,000 after buying an additional 5,218 shares in the last quarter. Finally, Toth Financial Advisory Corp raised its holdings in shares of Axon Enterprise by 35.7% during the 3rd quarter. Toth Financial Advisory Corp now owns 475 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 125 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.